Lantheus Holdings - LNTH Earnings per share for the trailing year

Lantheus Corp (LNTH) - corporate logo

Lantheus Holdings, Inc. (LNTH) price action has been driven by a strategy of total dominance in prostate diagnostics via Pylarify and the acquisition of biotech assets. A year-over-year EPS (TTM) comparison confirms this trend, with the parameter marked at 69.00. This has resulted in the company achieving gold standard status in oncology with growing revenue and the formation of a powerful core of leading radiologists, preventing the leakage of R&D competencies.

Lantheus Holdings, Inc. (LNTH): Net earnings per share for the last 12 months from 02/11/2024 to 11/18/2026

Financial and market metric breakdowns for Lantheus Holdings, Inc. (LNTH)

- stock price and consensus target price:
Fundamental company valuation:Lantheus Holdings LNTH
Original product of Lantheus Corp

The mass adoption of innovative contrast agents in cardiology provides Lantheus Holdings, Inc. (LNTH) with steady revenue, as reflected by the 12-month YoY earnings per share growth rate. The trend of rolling net income relative to market capitalization allows for a real-time assessment of the business's expansion speed, eliminating the risk of purchasing overvalued assets by synchronizing accounting data with continuous exchange quotes.